Literature DB >> 17578771

Point: antibiotic therapy is not the answer for patients with persisting symptoms attributable to lyme disease.

Paul G Auwaerter1.   

Abstract

It is not well understood why some patients develop a subjective syndrome that includes considerable fatigue, musculoskeletal aches, and neurocognitive dysfunction after receiving standard antibiotic courses for the treatment of Lyme disease. Some practitioners use the term "chronic Lyme disease" and order prolonged courses of oral and parenteral antibiotics, believing that persistent infection with Borrelia burgdorferi is responsible. However, well-performed prospective studies have found neither evidence of chronic infection nor a benefit worthy of long-term antibiotic therapy for these patients. Such extended antibiotic therapy poses hazards and cannot be viewed as acceptable. The term "chronic Lyme disease" should be discarded as misleading; rather, the term "post-Lyme disease syndrome" better reflects the postinfectious nature of this condition. Further research is necessary to understand possible mechanisms of these chronic symptoms following Lyme disease as well as to find effective therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17578771     DOI: 10.1086/518854

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  12 in total

1.  Guidelines for the management of lyme disease : the controversy and the quandary.

Authors:  William R Bowie
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 2.  Lyme arthritis: current concepts and a change in paradigm.

Authors:  Dean T Nardelli; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2007-11-14

Review 3.  Lyme disease--current state of knowledge.

Authors:  Roland Nau; Hans-Jürgen Christen; Helmut Eiffert
Journal:  Dtsch Arztebl Int       Date:  2009-01-30       Impact factor: 5.594

Review 4.  Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.

Authors:  Daniel J Cameron; Lorraine B Johnson; Elizabeth L Maloney
Journal:  Expert Rev Anti Infect Ther       Date:  2014-07-30       Impact factor: 5.091

5.  Antiscience and ethical concerns associated with advocacy of Lyme disease.

Authors:  Paul G Auwaerter; Johan S Bakken; Raymond J Dattwyler; J Stephen Dumler; John J Halperin; Edward McSweegan; Robert B Nadelman; Susan O'Connell; Eugene D Shapiro; Sunil K Sood; Allen C Steere; Arthur Weinstein; Gary P Wormser
Journal:  Lancet Infect Dis       Date:  2011-09       Impact factor: 25.071

6.  Decreased Th1-type inflammatory cytokine expression in the skin is associated with persisting symptoms after treatment of erythema migrans.

Authors:  Johanna Sjöwall; Linda Fryland; Marika Nordberg; Florence Sjögren; Ulf Garpmo; Christian Jansson; Sten-Anders Carlsson; Sven Bergström; Jan Ernerudh; Dag Nyman; Pia Forsberg; Christina Ekerfelt
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

7.  Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection.

Authors:  Monica E Embers; Stephen W Barthold; Juan T Borda; Lisa Bowers; Lara Doyle; Emir Hodzic; Mary B Jacobs; Nicole R Hasenkampf; Dale S Martin; Sukanya Narasimhan; Kathrine M Phillippi-Falkenstein; Jeanette E Purcell; Marion S Ratterree; Mario T Philipp
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

8.  Review of evidence for immune evasion and persistent infection in Lyme disease.

Authors:  Keith Berndtson
Journal:  Int J Gen Med       Date:  2013-04-23

9.  Vaccination against Lyme disease: Are we ready for it?

Authors:  Patricia Kaaijk; Willem Luytjes
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

10.  A Multiple Streams Approach to Understanding the Issues and Challenges of Lyme Disease Management in Canada's Maritime Provinces.

Authors:  Mario Levesque; Matthew Klohn
Journal:  Int J Environ Res Public Health       Date:  2019-04-30       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.